Nelarabine is an antineoplastic drug that is used to treat acute T-cell lymphoblastic leukemia. It inhibits DNA synthesis and causes cytotoxicity, and when added to standard chemotherapy, it enhances survival chances for children and young adults diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). In a clinical trial, 89% of patients with T-ALL with moderate to high risk of cancer relapse who received nelarabine in addition to standard chemotherapy had no signs or symptoms of leukemia compared to 83% of those who received chemotherapy alone.

T-cell malignancies have distinct immunologic, biochemical, and clinical features that set them apart from non-T-cell malignancies, and in the past, T-cell leukemia had a worse prognosis than leukemia of B-cell origin.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/3679

However, cure rates have improved with the intensification of therapy and an advanced understanding of the molecular genetics of T-cell malignancies. Nelarabine, a synthesized guanosine nucleoside prodrug of ara-G, has received accelerated approval by the U.S. FDA for relapsed/refractory T-ALL and T-LBL treatment in adults and children. Nelarabine is active as a single agent, which has led to the exploration of an expanded role in the treatment of T-cell hematologic malignancies.

The cure rate for acute lymphoblastic leukemia (ALL) has steadily increased since the 1960s, with the first success coming in the pediatric population. Advances in supportive care, precise risk assessment, intensification of therapy, and understanding the molecular genetics of leukemia cells have led to an improved outcome. The introduction of high-dose, multi-agent pulse chemotherapy has significantly improved the event-free survival (EFS) of children with T-cell ALL (T-ALL) from 15%-20% three decades ago to approximately 75% on the most recent published regimens.

The report on the nelarabine market includes a detailed study of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa regions. The regional outlook section analyzes region-wise revenue and volume for the forecast period of 2017 to 2027.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3679

Advancements in the healthcare sector will add to the revenue share of the nelarabine market, and rising awareness about health conditions and better facilities will create growth opportunities for the market. The market is expected to expand significantly in the developed regions of North America and Europe, where the advancement of the healthcare sector and investment in the sector is higher. However, since the disorder is common all over the world, the drug is in demand across all regions.

The competitive landscape section of the report enlists various leading manufacturers of the market. It provides an understanding of the strategies and collaborations that market players are focusing on to gain an edge over the competition in the industry. The global impacts of the coronavirus disease 2019 (COVID-19) are starting to be registered, and the nelarabine market will not be entirely an exception. However, the nelarabine market is expected to have an optimistic outlook over the forecast period as the drug is considered to be a first-in-class medication for the treatment of leukemia.

In summary, Nelarabine is an effective antineoplastic agent for the treatment of T-cell lymphoblastic leukemia, and adding it to standard chemotherapy enhances survival chances. The introduction of high-dose, multi-agent pulse chemotherapy has significantly improved the event-free survival of children with T-cell ALL, and advancements in the healthcare sector will add to the revenue share of the nelarabine market. The market is expected to expand significantly in the developed regions of North America and Europe, and the impact of COVID-19 on the nelarabine market is expected to be minimal.

 Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/3679

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Browse for more reports…